VJHemOnc is committed to improving our service to you

ASH 2019 | Time to treatment doesn’t impact outcome in intensively treated newly diagnosed AML

VJHemOnc is committed to improving our service to you

Christoph Röllig

Christoph Röllig, MD, MSc, of University Hospital Dresden, Dresden, Germany, explains how time from diagnosis to treatment does not affect outcome in intensively treated newly diagnosed acute myeloid leukemia (AML). This was determined through exploring the relationship between time between diagnosis, treatment and prognosis on a large set of real world data from the AML registry (NCT03188874) of the Study Alliance Leukemia (SAL) and comparing it to the published cohorts. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter